Typhoid, live attenuated

Active ingredient description

Typhoid, live attenuated, vaccine contains strains of Salmonella typhi, the etiological agent of typhoid fever, an acute, febrile enteric disease. The S. typhi Ty21a vaccine strain, by virtue of a reduction in enzymes essential for lipopolysaccharide biosynthesis, is restricted in its ability to produce complete lipopolysaccharide. However, a sufficient quantity of complete lipopolysaccharide is synthesized to evoke a protective immune response.

Medicine classification

This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:

ATC code Group title Classification
J07AP01 Typhoid, oral, live attenuated J Antiinfectives for systemic use → J07 Vaccines → J07A Bacterial vaccines → J07AP Typhoid vaccines
Discover more medicines within J07AP01

Product monographs

Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):

Title Information Source Document Type  
VIVOTIF Typhoid vaccine capsule FDA, National Drug Code (US) MPI, US: SPL/Old

External identifiers

DrugBank Drug: DB11050
RxNorm Ingredient: 762595
SNOMED-CT Concept: 764303004
Live typhoid vaccine (substance)
UNII Identifier: 0MZI008M96
SALMONELLA TYPHI TY21A LIVE ANTIGEN

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.